Mirvetuximab soravtansine (MIRV; Elahere; AbbVie) demonstrated significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer, showing particular promise in ...
The main market opportunities in the RSV prophylaxis field lie in the development of new monoclonal antibodies and vaccines, with substantial growth expected due to late-stage pipeline products. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback